HIV breakthroughs

O'Connor, Jeremy
August 1996
Financial World;8/12/96, Vol. 165 Issue 11, p16
Reports on the development of an anti-HIV drug known as protease inhibitors. Features of the drug; Impact on the level of HIV virus; Estimated amount of that the market for the drugs will grow within a year; Five companies that markets the drug.


Related Articles

  • Why anti-HIV drug loses effectiveness.  // USA Today Magazine;Oct96, Vol. 125 Issue 2617, p14 

    Reports on an investigation into why the anti-HIV drug saquinavir seems to lose effectiveness over time. Discovery of Jonathan M. Schapiro and associates that some people are not taking the drug as directed; How saquinavir, a protease inhibitor, works; Importance of taking the drug as prescribed.

  • HIV drug scare.  // New Scientist;9/07/96, Vol. 151 Issue 2046, p13 

    Reports on the warnings received by doctors in Europe after the approval of the use of ritonavir, a protease inhibitor, to treat HIV. Drug's ability to cause spontaneous bleeding in hemophiliacs.

  • Physicians face new contradictions HIV care. Voelker, Rebecca // JAMA: Journal of the American Medical Association;05/21/97, Vol. 277 Issue 19, p1504 

    Reports that the life-extending properties of protease inhibitors have created a clinical paradox for physicians treating patients infected with the human immunodeficiency virus (HIV). Comments by Lisa Capaldini, MD, at the 9th National AIDS Update Conference;Controversy as to when to start...

  • Amprenavir made available through early access program.  // AIDS Patient Care & STDs;Dec98, Vol. 12 Issue 12, p939 

    Announces the availability of the investigational anti-HIV protease inhibitor Agenerase to patients failing protease inhibitor-containing regimens through an early access program. Three options for obtaining the Agenerase drug under the early access program; Requirement for patients to receive...

  • Agenerase shows promise in treatment-naive and treatment-experienced HIV patients.  // AIDS Patient Care & STDs;Feb99, Vol. 13 Issue 2, p128 

    Reports on a small pilot study which evaluated the safety and efficacy of the HIV drug Agenerase in a double protease inhibitor regimen in the absence of NRTI therapy. Presentation of results at the 4th International Congress on Drug Therapy in Infection; Promise of Agenerase in treatment-naive...

  • FDA quickly approves indinavir.  // Dermatology Times;Aug96, Vol. 17 Issue 8, p60 

    Cites the Food and Drug Administration's (FDA) approval of indinavir (Crixivan) by Merck & Co. Indinavir as a member of the protease inhibitor drug class for use with nucleoside analogs to treat HIV infection; Reduction of the AIDS virus to nondetectable levels.

  • Unusual Distributions of Body Fat in AIDS Patients: A Review of Adverse Events Reported to the Food and Drug Administration. Mann, Marianne; Piazza-Hepp, Toni // AIDS Patient Care & STDs;May99, Vol. 13 Issue 5, p287 

    Examines the association between protease inhibitor therapy and unusual fat accumulations in HIV-infected individuals. Databases of the MEDWATCH system; Incidence of fat accumulation among HIV-patients without taking protease inhibitors; Reaction of patients to therapy.

  • A New HIV Treatment Gets Accelerated Approval.  // RN;Feb2001, Vol. 64 Issue 2, p103 

    Reports on the approval of protease inhibitor Kaletra for the treatment of HIV infections in adults and children over six months of age. Adverse effects of Kaletra.

  • Indinavir: A Review of its Use in the Management of HIV Infection. Plosker, G.L.; Noble, S. // Drugs;Dec1999, Vol. 58 Issue 6, p1165 

    Indinavir is a protease inhibitor used in the treatment of patients with HIV infection. Combination antiretroviral therapy with indinavir plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is associated with greater reductions in viral load, greater increases in CD4+ cell counts, and...


Read the Article

Other Topics